Oncotelic Therapeutics Engages IBN to Lead Corporate Communications Strategy

Oncotelic Therapeutics, Inc. (OTCQB: OTLC), a clinical-stage biopharmaceutical company developing RNA-based immunotherapy and targeted treatments for cancer and underserved diseases, has announced the selection of IBN to lead its corporate communications efforts. The company is currently advancing therapies for difficult-to-treat and rare conditions, including pediatric cancers and aggressive solid tumors, with its lead candidate OT-101 in a Phase 3 trial for pancreatic ductal adenocarcinoma.

The engagement of IBN, a specialized communications platform within the Dynamic Brand Portfolio, represents a strategic move to enhance Oncotelic's visibility and investor communications. IBN provides access to a vast network of wire solutions via https://ibn.fm/PTeNg, offering article and editorial syndication to over 5,000 outlets, enhanced press release services, and comprehensive social media distribution to millions of followers. This partnership could significantly improve market awareness of Oncotelic's innovative pipeline and clinical progress.

Led by Chairman and CEO Dr. Vuong Trieu, co-inventor of Abraxane, Oncotelic is building a multi-asset pipeline supported by its proprietary AI platform PDAOAI. The company maintains a 45% stake in GMP Biotechnology Limited, a joint venture with Dragon Capital Overseas Limited capable of supporting regulatory filings for up to 20 drug candidates. This diversified approach to drug development, combining internal research with strategic partnerships, positions Oncotelic to address high-unmet-need cancers and rare pediatric indications more effectively.

The implications of this corporate communications partnership extend beyond mere publicity. For investors and the broader biopharmaceutical industry, enhanced communication through platforms like IBN can lead to better market understanding of complex therapeutic developments, potentially influencing investment decisions and partnership opportunities. The company's latest news and updates relating to OTLC are available in its newsroom at https://ibn.fm/OTLC, providing stakeholders with centralized access to critical information.

For patients and healthcare providers following advancements in cancer treatment, improved corporate communications mean better access to information about promising therapies in development. Oncotelic's focus on RNA-based treatments and immunotherapy represents a growing segment of oncology research that could offer new options for conditions with limited treatment alternatives. The company's extensive intellectual property portfolio, including over 150 patent applications and 39 issued U.S. patents held by Dr. Trieu, underscores the innovative nature of its approach to drug development.